Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA

Barbara Mintzes, Morris L. Barer, Richard L. Kravitz, Ken Bassett, Joel Lexchin, Arminée Kazanjian, Robert G. Evans, Richard Pan and Stephen A. Marion
CMAJ September 02, 2003 169 (5) 405-412;
Barbara Mintzes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morris L. Barer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard L. Kravitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Bassett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Lexchin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arminée Kazanjian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert G. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Pan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen A. Marion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Direct-to-consumer advertising (DTCA) of prescription drugs has increased rapidly in the United States during the last decade, yet little is known about its effects on prescribing decisions in primary care. We compared prescribing decisions in a US setting with legal DTCA and a Canadian setting where DTCA of prescription drugs is illegal, but some cross-border exposure occurs.

Methods: We recruited primary care physicians working in Sacramento, California, and Vancouver, British Columbia, and their group practice partners to participate in the study. On pre- selected days, patients aged 18 years or more completed a questionnaire before seeing their physician. We asked these patients' physicians to complete a brief questionnaire immediately following the selected patient visit. By pairing individual patient and physician responses, we determined how many patients had been exposed to some form of DTCA, the frequency of patients' requests for prescriptions for advertised medicines and the frequency of prescriptions that were stimulated by the patients' requests. We measured physicians' confidence in treatment choice for each new prescription by asking them whether they would prescribe this drug to a patient with the same condition.

Results: Seventy-eight physicians (Sacramento n = 38, Vancouver n = 40) and 1431 adult patients (Sacramento n = 683, Vancouver n = 748), or 61% of patients who consulted participating physicians on pre-set days, participated in the survey. Exposure to DTCA was higher in Sacramento, although 87.4% of Vancouver patients had seen prescription drug advertisements. Of the Sacramento patients, 7.2% requested advertised drugs as opposed to 3.3% in Vancouver (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.2–4.1). Patients with higher self- reported exposure to advertising, conditions that were potentially treatable by advertised drugs, and/or greater reliance on advertising requested more advertised medicines. Physicians fulfilled most requests for DTCA drugs (for 72% of patients in Vancouver and 78% in Sacramento); this difference was not statistically significant. Patients who requested DTCA drugs were much more likely to receive 1 or more new prescriptions (for requested drugs or alternatives) than those who did not request DTCA drugs (OR 16.9, 95% CI 7.5–38.2). Physicians judged 50.0% of new prescriptions for requested DTCA drugs to be only “possible” or “unlikely” choices for other similar patients, as compared with 12.4% of new prescriptions not requested by patients (p < 0.001).

Interpretation: Our results suggest that more advertising leads to more requests for advertised medicines, and more prescriptions. If DTCA opens a conversation between patients and physicians, that conversation is highly likely to end with a prescription, often despite physician ambivalence about treatment choice.

View Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (5)
CMAJ
Vol. 169, Issue 5
2 Sep 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
Barbara Mintzes, Morris L. Barer, Richard L. Kravitz, Ken Bassett, Joel Lexchin, Arminée Kazanjian, Robert G. Evans, Richard Pan, Stephen A. Marion
CMAJ Sep 2003, 169 (5) 405-412;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
Barbara Mintzes, Morris L. Barer, Richard L. Kravitz, Ken Bassett, Joel Lexchin, Arminée Kazanjian, Robert G. Evans, Richard Pan, Stephen A. Marion
CMAJ Sep 2003, 169 (5) 405-412;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Supported by an unrestricted educational grant
  • Direct-to-consumer prescription drug advertising in Canada: Permission by default?
  • PubMed
  • Google Scholar

Cited By...

  • Ethical drug marketing criteria for the 21st century
  • Why the drug development pipeline is not delivering better medicines
  • Associations between Cancer-Related Information Seeking and Receiving PET Imaging for Routine Cancer Surveillance--An Analysis of Longitudinal Survey Data
  • Attention-deficit/hyperactivity disorder: are we helping or harming?
  • Pediatric neuroenhancement: Ethical, legal, social, and neurodevelopmental implications
  • The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
  • Should Canada allow direct-to-consumer advertising of prescription drugs?: NO
  • Le Canada devrait-il autoriser la publicite directe des medicaments d'ordonnance?: NON
  • Should Canada allow direct-to-consumer advertising of prescription drugs?: YES
  • Le Canada devrait-il autoriser la publicite directe des medicaments d'ordonnance?: OUI
  • Lack of Impact of Direct-to-Consumer Advertising on the Physician-Patient Encounter in Primary Care: A SNOCAP Report
  • AOA Symposium: Direct-to-Consumer Marketing in Orthopaedic Surgery: Boon or Boondoggle?
  • Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study
  • Continuing medical education in the 21st century
  • La publicite directe au consommateur : fini les compromis
  • Direct-to-consumer advertising: end the compromise
  • Time to Ban Direct-to-Consumer Prescription Drug Marketing
  • Direct-to-Consumer Advertising in Oncology.
  • Smart Regulation: Will the government's strategy work?
  • Benefits and harms of direct to consumer advertising: a systematic review
  • Direct-to-consumer advertising
  • Direct-to-consumer advertising
  • Direct-to-consumer advertising
  • Does Direct-to-Consumer Drug Advertising Affect Prescribing Behavior?
  • Does Direct-to-Consumer Drug Advertising Affect Prescribing Behavior?
  • Does Direct-to-Consumer Drug Advertising Affect Prescribing Behavior?
  • Minerva
  • Annonces et blocs d'ordonnances
  • Ads and prescription pads
  • Google Scholar

More in this TOC Section

  • Emergency department use following incentives to provide after-hours primary care: a retrospective cohort study
  • Physician choices in pulmonary embolism testing
  • Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta
Show more Research

Similar Articles

Collections

  • Topics
    • Pharmacology & toxicology
    • Patient education
    • Medical ethics

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire